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ebastian Kufner, MD,* Jörg Hausleiter, MD,* Gjin Ndrepepa, MD,* Stefanie Schulz, MD,*
lga Bruskina, MD,* Robert A. Byrne, MB,* Massimiliano Fusaro, MD,†
dnan Kastrati, MD,* Albert Schömig, MD,*† Julinda Mehilli, MD,* for the
SIRIS Trial Investigators
unich, Germany
bjectives We sought to investigate the long-term efﬁcacy of oral sirolimus therapy and its impact
n the incidence of de novo malignancies in the OSIRIS (Oral Sirolimus to Inhibit Recurrent In-Stent
tenosis) trial population.
ackground The OSIRIS trial showed a signiﬁcant reduction of angiographic restenosis with an oral
djunctive sirolimus treatment for in-stent restenosis. The long-term efﬁcacy of oral sirolimus ther-
py is unknown.
ethods Three hundred patients with in-stent restenosis were randomly assigned to receive pla-
ebo, a cumulative loading dose of 8 mg (usual-dose), or 24 mg (high-dose) of sirolimus over 3 days
2 days before and the day of intervention) followed by maintenance therapy of 2 mg/day for 7
ays. The primary outcome of this analysis was the incidence of composite of death, myocardial in-
arction, and target vessel revascularization at 4-year follow-up. Secondary outcome was the inci-
ence of newly diagnosed malignancies.
esults No signiﬁcant differences were observed between placebo, usual-, and high-dose sirolimus
reatment groups regarding primary outcome (33.3%, 39.4%, and 31.3%, respectively; p  0.46),
eath (5.9%, 9.1%, and 11.1%, respectively; p  0.41), target vessel revascularization (30.4%, 30.3%,
nd 22.2%, respectively; p  0.33), and rate of newly diagnosed malignancies (7.8%, 3.0%, and
1.1%, respectively; p  0.09).
onclusions The beneﬁt in the reduced need for repeat intervention observed at 1 year with high-
ose oral sirolimus therapy was attenuated over 4 years. Moreover, this regimen was associated
ith numerical yet not a signiﬁcant increase in newly diagnosed malignancies without augmenting
he malignancy-induced risk of death. (Oral Sirolimus for In-Stent Restenosis [OSIRUS] trial;
CT00859183) (J Am Coll Cardiol Intv 2009;2:1142–8) © 2009 by the American College of
ardiology Foundation
rom the *Deutsches Herzzentrum, Technische Universität, Munich, Germany; and †1. Medizinische Klinik rechts der Isar,
echnische Universität, Munich, Germany.anuscript received June 1, 2009; revised manuscript received August 17, 2009, accepted August 20, 2009.
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1143he use of immunosuppressive drugs to prevent and treat
eointimal hyperplasia after percutaneous coronary inter-
entions (PCIs) heralded a new era in interventional cardi-
logy. Both new stent platforms able to locally release drugs
o the vessel wall and orally administered immunosuppres-
ive drugs have been tested (1–7). Due to its ability to
nhibit the proliferation of vascular smooth muscle cells,
irolimus was quickly adopted for local drug delivery using a
rug-eluting stent (DES) platform or as an adjunctive
ystemic therapy to catheter-based intervention (8). High-
ose oral therapy with sirolimus before and after PCI has
een reported to reduce the need for repeat revascularization
ot only after stenting of de novo lesions (2,4,5) but also
fter balloon angioplasty for recurrent bare-metal in-stent
estenosis (ISR) (1,3). In patients with ISR enrolled in the
SIRIS (Oral Sirolimus to Inhibit Recurrent In-stent
tenosis) trial (3), oral adjunctive sirolimus treatment with
n intensified loading regimen before PCI resulted in a 47%
eduction in angiographic restenosis and a 40% lower rate of
epeat revascularization at 1 year.
Hand in hand with its desired antiproliferative properties,
owever, immunosuppressive therapy may increase the risk
f malignancy due to its negative impact on immunosur-
eillance (9). This risk seems to be present not only in
atients receiving immunosuppressive drugs for solid organ
ransplantation but also for other conditions even when
reated with a single, low-dose therapy (10). There are no
ata about the long-term impact of short-term, high-dose
mmunosuppressive drugs in cardiac patients. In a recently
ublished meta-analysis involving nonindividual patient
ata, an increased rate of malignancy-induced death at 1
ear after sirolimus-eluting stent implantation in cardiac
atients has been reported (11).
We extended the follow-up period of the OSIRIS trial up
o 4 years to assess: 1) whether the 1-year benefit of oral
irolimus therapy is maintained at long-term follow-up; and
) whether the high-dose oral sirolimus increases the risk of
e novo malignancies over this period.
ethods
atients and protocol. The OSIRIS trial design and pa-
ients were described previously (3). Briefly, patients with
ymptomatic bare-metal ISR in native coronary arteries and
ithout acute coronary syndromes, severe infectious dis-
ases, or severe renal insufficiency were enrolled. All patients
ad given their written informed consent for participation in
his trial. The study was conducted according to the
rinciples of the Declaration of Helsinki and approved by
he institutional ethics committees. Randomization was
erformed in the catheterization laboratory after the diag-
osis of ISR was established by angiography. Patients were
ssigned in a double-blind fashion to 1 of the 3 study arms:
lacebo, usual-dose sirolimus, or high-dose sirolimus. The psual- and high-dose sirolimus groups received an oral
ntensified loading with a total dose of 8 mg and 24 mg of
irolimus, respectively, over 3 days (2 days before and the
ay of PCI procedure) (3). After repeat PCI, the mainte-
ance dose of 2 mg/day of sirolimus or placebo was
ontinued for 7 days. Recommended procedure to treat ISR
as conventional balloon angioplasty with provisional stent-
ng in case of suboptimal results or large residual dissection
fter angioplasty. The post-procedural antithrombotic reg-
men consisted of 75 mg of clopidogrel for at least 6 months
nd 100 mg of aspirin twice daily indefinitely.
ata management, deﬁnitions, and study end points. An-
iographic restenosis at 6-month follow-up angiogram
efined as diameter stenosis 50% and the combined
ncidence of death, myocardial infarction (MI), and
schemia-driven target vessel revascularization (TVR) (PCI
r bypass surgery) during 1-year follow-up were primary
nd secondary end points of the OSIRIS trial. The defini-
ion of end points and the methodology of their evaluation
ave been previously described (3). All adverse events were
djudicated and classified by an event adjudication commit-
ee whose members were un-
ware of the patients’ assigned
reatment after review of original
ource documentation. Quanti-
ative and qualitative core angio-
raphic laboratory analysis was
erformed blinded to assigned
reatment and clinical outcomes
ith the use of previously de-
cribed methodology (3).
The primary outcome of the
urrent study was the composite
f death, MI, or TVR at 4 years after randomization. The
econdary outcome was the incidence of de novo malignan-
ies over the same period. The incidence of individual
omponents of the primary end point was also assessed. The
atients’ clinical follow-up consisted of annual telephone
nterviews, and, in case the patients reported cardiac symp-
oms during the interview, a complete clinical, electrocar-
iogram, and laboratory examination was performed in the
utpatient clinic or by the referring physician. Questions
bout the new diagnosis of any kind of malignant diseases as
ell as its therapy were also part of the interview. Every
iagnosis of malignant disease reported by the patient or
ound out in the Bavarian Tumour Registry, as well as the
ate of first diagnosis, was evaluated using patients’ dis-
harge summaries. No patient moved from the geographic
egion during the follow-up period. De novo malignancy
as defined as any new diagnosed malignant disease after
he administration of immunosuppressive therapy.
tatistical analysis. The data are analyzed according to the
ntention-to-treat principle. Categorical variables are ex-
Abbreviations and
Acronyms
DES  drug-eluting stent(s)
ISR  in-stent restenosis
MI  myocardial infarction
PCI  percutaneous
coronary intervention
TVR  target vessel
revascularizationressed as counts or percentages and compared by chi-
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1144quare test or Fisher exact test, as appropriate. Survival
nalysis was performed by applying the Kaplan-Meier
ethod. Differences in survival were assessed with the
og-rank test. Survival free of adverse events was defined as
he interval from randomization until the event of interest.
ata for patients who did not have an event of interest were
ensored at the date of the last follow-up. All analyses were
erformed using S-plus statistical package (S-PLUS, In-
ightful Corp., Seattle, Washington). A p value 0.05 was
onsidered to indicate statistical significance.
esults
etailed information on baseline characteristics of patients
ssigned to placebo, usual-dose sirolimus, or high-dose
irolimus has been reported in the primary publication. In
rief, a quarter of patients were women, one-third of them
resented with diabetes mellitus, mean vessel size was 2.6
m, 50% of lesions were treated for diffuse ISR, and a new
tent implantation was needed in 10% to 16% of patients.
here were no significant differences in the baseline char-
cteristics between patients in the 3 study groups.
linical outcome at 4 years. Four-year clinical follow-up was
ompleted in all patients. The incidence of the primary
utcome of interest—death, MI, or TVR—was 33.3% (n
4) in the placebo group, 39.4 % (n  39) in the usual-dose
irolimus group, and 31.3% (n  31) in the high-dose
irolimus group (p  0.46) (Fig. 1). Six patients (5.9%) in
he placebo group, 9 patients (9.1%) in the usual-dose
irolimus group, and 11 patients (11.1%) in the high-dose
irolimus group died during the 4-year period (p  0.41).
he cause of death for each patient is shown in Table 1.
wo patients experienced MI, one in the usual-dose siroli-
Figure 1. Primary Outcome of Interest
Kaplan-Meier curves for survival free of myocardial infarction and target
vessel revascularization for placebo, usual-dose, or high-dose sirolimus
groups at 4 years.us group and the other in the high-dose sirolimus group (p  0.61). No differences were observed in death or MI
ates between the 3 groups: 7 patients (6.9%) in the placebo
roup, 9 patients (9.1%) in the usual-dose sirolimus group,
nd 12 patients (12.1%) in the high-dose sirolimus group
p  0.44) (Fig. 2). TVR was required in 31 patients
30.4%) treated with placebo, in 30 patients (30.3%) treated
ith usual-dose sirolimus, and in 22 patients (22.2%)
reated with high-dose sirolimus (p  0.33) (Fig. 3).
oronary bypass surgery was performed in only 1 patient in
he high-dose sirolimus group. Target lesion revasculariza-
ion was required in 26 patients (25.5%) treated with
lacebo, in 25 patients (25.3%) treated with usual-dose
irolimus, and 16 patients (16.2%) treated with high-dose
irolimus (p  0.20) (Table 2). Between 1 and 4 years
ollow-up, no differences were observed in any of the clinical
utcomes (Table 2).
mpact of sirolimus dose on malignancies. The overall inci-
ence of malignancies in the OSIRIS trial population was
4.0% (n  42). Of them, 7 patients (6.9%) in the placebo
roup, 12 patients (12.1%) in the usual-dose sirolimus
roup, and 6 patients (6.1%) in the high-dose sirolimus
roup (p 0.24) already had a malignant disease at the time
f randomization. At 4 years, a total of 22 patients (7.3%)
ere diagnosed as having a de novo malignant disease: 8
atients (7.8%) in the placebo group, 3 patients (3.0%) in
he usual-dose sirolimus group, and 11 patients (11.1%) in
he high-dose sirolimus group (p  0.09). Second malig-
ant diseases occurred in 3 patients, 1 in each group. The
umulative incidence and the distribution of newly diag-
osed malignancies in all 3 groups are shown in Figures 3
nd 4. The median elapsed time from oral drug adminis-
ration to the diagnosis of de novo malignancies was 17
onths (range 3 to 48 months).
iscussion
ata of extended follow-up of the OSIRIS trial provide the
nly currently available randomized evidence comparing the
ong-term consequences of oral sirolimus at high or usual
ose versus placebo in patients undergoing repeat PCI for
are-metal in-stent restenosis. Over 4 years, we observed a
ecline in the initially demonstrated restenosis reduction
ffect with the intensive regimen of oral sirolimus therapy
ompared with placebo. Additionally, the risk of developing
e novo malignancies after this high-dose short-term im-
unosuppressive therapy was not increased.
Treatment of ISR remains a formidable challenge. De-
pite very poor results (20% to 30% repeat revascularization
ates), percutaneous transluminal coronary angioplasty alone
s the most widely used revascularization strategy in those
atients (12–16). Experience with intracoronary radiation
herapy has shown excellent acute and short-term results at
he expense of increased late stent thrombosis and mortality
17). While repeat implantation of bare-metal stents failed
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1145s a treatment option for recalcitrant restenosis (12,18), the
xcellent results with DES in de novo lesions encouraged
heir use to treat this disease (16).
Figure 2. Incidence of Target Vessel Revascularization for Placebo, Usual-
Table 1. Summary of Patients Who Died at Follow-Up
Patient # Age, yrs Group
1 69 Placebo
2 65 Placebo
3 66 Placebo
4 64 Placebo
5 83 Placebo
6 74 Placebo
7 82 Usual dose
8 74 Usual dose
9 60 Usual dose
10 68 Usual dose
11 68 Usual dose
12 70 Usual dose
13 73 Usual dose
14 67 Usual dose
15 67 Usual dose
16 77 High dose
17 68 High dose
18 80 High dose
19 74 High dose
20 62 High dose
21 73 High dose
22 79 High dose
23 71 High dose
24 75 High dose
25 78 High dose
26 84 High dose
MOFmultiorgan failure; OS orthopedic surgery; PCI percutaneiDose Sirolimus, or High-Dose Sirolimus Groups at 1- and 4-Year Follow-UpPeri-interventional systemic administration of immuno-
uppressive drugs was associated with a reduction in repeat
evascularization rates comparable with that of DES im-
lantation in the de novo native coronary artery lesions (7).
n the OSIRIS trial, patients presenting with recurrent
are-metal in-stent restenosis and treated before and after
CI with oral sirolimus showed a significant reduction of
estenosis during the first year. We and others have shown
direct association between sirolimus blood concentration
t the time of PCI and late lumen loss (3,4,7). A blood level
f 18 g/l with high-dose sirolimus loading and 10 g/l
ith maintenance dose for a week was associated with late
umen loss of 0.49 mm, which is very similar to the late loss
alues observed with polymer-based, paclitaxel-eluting
tents or polymer-free, sirolimus-eluting stents (19,20).
However, expanding the follow-up up to 4 years in this
nalysis of the OSIRIS trial, the initially observed benefit
or reduction of restenosis particularly with the high-dose
egimen was not sustained. Although the absolute difference
Interval Procedure
o Death, Days Cause of Death
472 Ischemic stroke
561 Malignancy related
718 Malignancy related
732 Sudden death
742 Sudden death
779 Sudden death
27 Cerebral bleeding
173 Septicemia after OS
215 Myocardial infarction
458 Ischemic stroke
758 Sudden death
967 Terminal renal failure
1,140 Malignancy related
1,319 Malignancy related
1,345 Terminal renal failure
14 Sudden death after OS
additional PCI procedure
66 Cardiogenic shock with MOF
multiorgan failure
199 Ischemic stroke
658 Malignancy related
756 Sudden death
849 Noncardiac surgery
877 Sudden death
887 Sudden death
956 Malignancy related
1,016 Malignancy related
1,420 Sudden death
nary intervention.Time
tn the target lesion and vessel revascularization rates re-
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1146ained nearly constant, the observed relative reduction of
epeat revascularization rates by 40% within the first year
fter peri-interventional administration of high-dose siroli-
us therapy declined at year 4 to a nonsignificant 27%. To
ur knowledge there are no long-term data about the
ntirestenotic effects of any oral immunosuppressive therapy
n patients with coronary artery disease. However, the same
henomenon of attenuation of antirestenotic efficacy at
ong-term angiographic surveillance has been reported for
ES—albeit to a lesser degree (21).
Figure 3. Cumulative Incidence of Newly Diagnosed Malignancies for
Placebo, Usual-Dose Sirolimus, or High-Dose Sirolimus Groups at 4 Years
Table 2. Clinical Outcome
Outcomes
Placebo
(n  102)
At 1-yr follow-up, %
Death 0
Myocardial infarction 1.0
Death or myocardial infarction 1.0
Target lesion revascularization 22.5
Target vessel revascularization 25.5
MACE rate 27.5
Between 1 and 4 yrs of follow-up, %
Death 5.9
Myocardial infarction 0
Death or myocardial infarction 5.9
Target lesion revascularization 3.0
Target vessel revascularization 4.9
MACE rate 5.8
At 4 years follow-up, %
Death 5.9
Myocardial infarction 1.0
Death or myocardial infarction 6.9
Target lesion revascularization 25.5
Target vessel revascularization 30.4
MACE rate 33.3MACEmajor adverse cardiac events.Among other factors, the long-term outcome of patients
eceiving systemic immunosuppressive drugs depends on
he development of de novo malignancies. Data from large
egistries have shown an overall 3- to 5-fold increase in
alignancy risk in transplant recipients compared with the
ge-matched general population (22). While there is a
Figure 4. Distribution of Different Entities of De Novo Malignancies for
Placebo, Usual-Dose Sirolimus, or High-Dose Sirolimus Groups at 4 Years
CNS  central nervous system; CUP  cancer of unknown primary origin;
NHL  non-Hodgkin lymphoma.
ual-Dose Sirolimus
(n  99)
High-Dose Sirolimus
(n  99) p Value
3.0 2.0 0.23
0 0 0.23
3.0 2.0 0.59
22.2 12.1 0.10
24.2 15.2 0.08
29.3 18.2 0.15
6.1 9.1 0.61
0 1.1 0.36
6.1 10.1 0.43
3.1 4.1 0.95
6.1 7.0 0.79
10.1 13.1 0.22
9.1 11.1 0.41
0 1.1 0.61
9.1 12.1 0.44
25.3 16.2 0.20
30.3 22.2 0.33
39.4 31.3 0.46Us
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1147eneral agreement about the pro-neoplastic effect of some
mmunosuppressive drugs such as azathioprine or cyclospo-
ine, there are conflicting data about the role of mammalian
arget of rapamycin inhibitors (10,23). The drastic regres-
ion of the human herpes virus 8-induced Kaposi sarcoma
fter administration of sirolimus is clear evidence of anti-
eoplastic effect of mTOR inhibitors (24). However, in the
LITE (Efficacy Limiting Toxicity Elimination)–
ymphony study, which investigated 4 different immuno-
uppressive drugs in 1,645 kidney transplant recipients, the
ighest de novo malignancy rate was observed in the
irolimus group (25). The carcinogenic effect seems to be
resent not only for solid organ recipients requiring main-
enance immunosuppressive therapy but also for patients
uffering from other conditions even when treated with a
ingle, low-dose therapy (10). Moreover, the first experience
ith first-generation sirolimus-eluting coronary stents has
hown some worrisome signals of increased long-term
ancer-induced mortality in patients receiving these stents
ompared with the control group, who received bare-metal
tents (11).
Although only for a short-time of 10 days, in the OSIRIS
rial we used a high-dose of sirolimus. However, the overall
ncidence of de novo malignancies during the 4-year
ollow-up was nearly 8%, very similar to that of the general
opulation (between 11% and 13%) (26). Immunosupres-
ive drugs favor the development of rare tumor entities,
hich tend to be biologically more aggressive than those
hat occur in the general population (23). The distribution
attern of different types of de novo malignancies in the
SIRIS trial population reflects the same distribution as in
he general population (26).
tudy limitations. First, the OSIRIS study was powered to
etect differences in ISR. Although the 4-year clinical
ollow-up was complete for all patients, the relatively low
umber of patients enrolled precludes definitive conclusions
bout differences in clinical outcomes. Second, after the first
ollow-up year, there were no repeat angiographic studies
lanned. This reduced the ability of the study to assess the
ery long-term effect of different drug regimens in angio-
raphic restenosis. However, this allowed us to evaluate
ore reliably the incidence of clinically driven repeat revas-
ularization in this population. Third, analysis regarding
alignancies was not pre-specified in the study protocol.
ourth, we do not have any information about disease
rogression after immunosuppressive therapy in patients
ith established cancer diagnoses. Moreover, a time interval
f 4 years probably is not long enough to fully capture the
ro-neoplastic effects of a certain drug. Finally, this study
ncludes multiple statistical tests. This should be taken into
ccount when considering the statistical significance of the
ifferences among the 3 groups.onclusions
he benefit in the reduced need for repeat intervention
bserved at 1 year with high-dose oral sirolimus therapy was
ttenuated over 4 years. Moreover, this regimen was asso-
iated with a numerical, yet not significant, increase in
ewly diagnosed malignancies without augmenting the
alignancy-induced risk of death.
eprint requests and correspondence: Dr. Julinda Mehilli,
eutsches Herzzentrum, Lazarettstr. 36, 80636 München, Ger-
any. E-mail: mehilli@dhm.mhn.de.
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